Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.41 |
| ▸ | CES1 | P23141 | 6/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | ODC1 | P11926 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6224514 | 0.88 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL359979 | 0.88 | FAAH (0.39) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL1995668 | 0.87 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL2577585 | 0.85 | DNM1 (0.52) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL15711042 | 0.85 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3149138 | 0.85 | HRH4 (0.41) | CYP1A2KMT2AHRH4HRH3ODC1 | |
| Trifluoroacetic Acid SCHEMBL10619788 | 0.85 | HRH4 (0.41) | CYP1A2KMT2AHRH4HRH3ODC1 | |
| Hexadecylamine SCHEMBL23001148 | 0.84 | DNM1 (0.56) | FAAHCES1CES2MEN1CYP1A2 | |
| Decylamine SCHEMBL28610774 | 0.84 | DNM1 (0.56) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL29282412 | 0.84 | DNM1 (0.56) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011108955-A1 | MULTI -TARGETING SYSTEM COMPRISING A NANOCARRIER, NUCLEIC ACID(S) AND NON-NUCLEIC ACID BASED DRUG(S) | UNIVERSIDADE DE COIMBRA (PT) | 2011-09-09 | — | — | WO | claimed |
| WO-1996020592-A1 | METHOD FOR INACTIVATING NON-ENVELOPED VIRUSES USING A VIRICIDE-POTENTIATING AGENT | HEMASURE INC. (US) | 1996-07-11 | — | — | WO | claimed |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | THE TRUSTEES OF THE UNIV OF PENNSYLVANIA (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090156-A1 | 1,3,5-TRIAZINANE-2,4,6-TRIONE-DERIVED IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLES (LNPS) COMPRISING THE SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4724465-A1 | COMPOSITIONS AND METHODS FOR GENERATING IMMUNITY TO BACTERIAL INFECTION | Syntiron LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12600971-B2 | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | BEAM THERAPEUTICS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260083861-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSION | EDITAS MEDICINE, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | UNIV PENNSYLVANIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260054197-A1 | SYSTEM FOR RECOVERING ANTIGEN IN SOLVENT AND METHOD FOR RECOVERING ANTIGEN IN SOLVENT | GOGEN TECH LTD (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260002159-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | EDITAS MEDICINE INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-0923284-A4 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | ALLEGHENY UNIVERSITY OF THE HE (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1242609-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | Novartis AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049324-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | NOVARTIS AG (CH) | 2001-07-12 | — | — | WO | disclosed |
| EP-0783482-A4 | CATIONIC TRANSPORT REAGENTS | UNIV CALIFORNIA (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0923284-A1 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | Allegheny University of The Health Sciences (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997025860-A1 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | ALLEGHENY UNIVERSITY OF THE HEALTH SCIENCES (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0783482-A1 | CATIONIC TRANSPORT REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010555-A9 | CATIONIC TRANSPORT REAGENTS | — | 1996-06-13 | — | — | WO | disclosed |
| WO-1996010555-A1 | CATIONIC TRANSPORT REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | UPF1, RPRD2, NR2E3 | FAAH 3223/4885CES1 3416/4885CES2 3964/4885 |
| US-20260137630-A1 | COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS | LCP2, CD47, CD4 | FAAH 1840/4885CES1 295/4885CES2 742/4885 |
| US-12600971-B2 | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | CDA, ADAR, ADA | FAAH 4253/4885CES1 3005/4885CES2 3937/4885 |
| US-20260083861-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSION | CD74, CD2, CD4 | FAAH 4882/4885CES1 3154/4885CES2 4298/4885 |
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | BCR, PHOSPHO1, BST2 | FAAH 1005/4885CES1 803/4885CES2 3782/4885 |
| US-20260002159-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | CBLB, CBL, BCL9L | FAAH 4834/4885CES1 2582/4885CES2 3660/4885 |
| US-20260054197-A1 | SYSTEM FOR RECOVERING ANTIGEN IN SOLVENT AND METHOD FOR RECOVERING ANTIGEN IN SOLVENT | CD14, CD44, CETP | FAAH 1552/4885CES1 216/4885CES2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.